Introduction
Mammalian LPPs were formerly known as Mg 2+ -independent and N-ethylmaleimide insensitive phosphatidate phosphatases (PAP2) (1-3). There are three LPPs (LPP1, -2 and -3 and a splice variant LPP1a), which hydrolyze lipid phosphates including PA, LPA, S1P, C1P and diacylglycerol pyrophosphate. (3) . They belong to a phosphatase/phosphotransferase family that includes S1P phosphatases, glucose 6-phosphatase and the sphingomyelin synthases (1, 2) . LPPs possess six transmembrane domains, three conserved active site domains and a glycosylation site on an hydrophilic loop between the first and second active site domains (1, 2, 4).
The active sites are located on the outer surface of plasma membranes, or the lumenal surface of internal membranes (1, 5) . Mammalian LPPs form homo-and hetero-oligomers, which are catalytically active compared to the monomeric forms (6) . These complexes could control their activities and subcellular distributions. However, work with Wunen, a Drosophila homologue of mammalian LPPs, showed that dimerization is not required for biological activity (7) .
This review will first assess how mammalian LPPs control signaling by the extracellular lipid phosphates.
Formation and significance of extracellular LPC, LPA and S1P
LPA is present at up to 10 µM in the blood (8, 9) . Extracellular LPA is implicated in cancer and its concentration is high in ascites fluid and plasma of patients with ovarian tumors (10) . LPA is also involved in wound repair and tissue development (1, 11) by promoting cell growth, proliferation, differentiation, motility and survival (1, 10) through at least six G-protein coupled receptors (12, 13) . These activate the phosphatidylinositol 3-kinase and ERK pathways, by guest, on August 15, 2017 www.jlr.org
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small G-proteins that affect cytoskeletal arrangements and they decrease the abundance of the p53 tumor suppressor (14) .
A major route for synthesizing extracellular LPA (Fig. 1A) is through the action of secreted ATX on LPC, which is present in blood at up to 200 µM (8) . ATX expression promotes tumor progression, metastasis, angiogenesis and it protects tumor cells from apoptosis (1). This occurs predominantly from the generation of LPA (15) . Saturated LPC is produced mainly by lecithin:cholesterol acyltransferase in circulating high-density lipoproteins (1). However, a large proportion of circulating LPC is polyunsaturated and this is partly derived from hepatocytes (16) .
A minor pathway for the production of saturated LPA is through secretory PLA 2 , which hydrolyzes PA in microvesicles that are shed from cells during inflammation (17) and platelet aggregation (18) . S1P is a sphingolipid analogue of LPA. S1P activates a family of five G-protein coupled receptors and it is important in regulating angiogenesis and immune responses (19) . S1P is present in blood at 0.2-0.9 µM where it is bound to albumin and lipoproteins. S1P is released from platelets to facilitate tissue repair and angiogenesis (20) . Red blood cells provide a major reservoir of S1P (19) . Circulating S1P can be derived from the extracellular action of sphingosine kinase and cells can secrete S1P as part of an autocrine/paracrine signaling loop (19) .
Dephosphorylation of extracellular lipid phosphates
Extracellular LPA and S1P are metabolized mainly by the ecto-activities of the LPPs (1, 2, 21) . Increasing LPP1 expression increases the dephosphorylation of exogenous PA, LPA and C1P (22) . Ecto-LPP activities appeared to be involved in signaling since LPP1 over-expressing by guest, on August 15, 2017 www.jlr.org
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fibroblasts attenuated LPA-induced activation of ERK, PLD, Ca 2+ transients, and cell division (22) . Gonadotropin-releasing hormone increased ecto-LPP expression in ovarian cancer cells and this explained its anti-proliferative effects (23) . LPP3 over-expression decreases growth, survival and tumorigenesis of ovarian cancer cells and it also decreases the ability of the parental cells to form colonies (24) . The effects of LPP-3 on colony-forming activity were substantially reversed by an LPP-resistant LPA analogue. In other studies, exogenous LPA increased ecto-LPP1 activity in platelets and this decreased further LPA accumulation and LPA-induced shape changes and aggregation (25) . Ecto-LPP activities also regulate extracellular LPA accumulation and proliferation of pre-adipocytes (26) . This combined work establishes a role for the ecto-LPP activities in regulating cell signaling by extracellular lipid phosphates.
Significantly, LPP1 expression is decreased in a majority of ovarian cancers (27) .
Increased expression of LPP1 in ovarian cancer cell lines increased LPA hydrolysis, decreased cell proliferation and colony forming activity and it increased apoptosis. It was concluded that the LPA-rich environment of ovarian cancer cells in vivo results from a combined increase in LPA production by ATX and decreased LPA removal by the LPPs (27) .
A further dimension of the ecto-LPP activity is that dephosphorylated products readily enter cells (1, 2) . The uptake of MAG following LPA dephosphorylation can increase intracellular LPA production by acylglycerol kinase (28) . Intracellular LPA can then activate internal signaling cascades (Table 1) .
Most monoacylglycerols (MAG) are devoid of biological activity except for 2-arachidonoylglycerol (2-AG), which is an activator of cannabinoid (CB1 and CB2) receptors ( been described (29) . Also, the 2-AG produced by the LPPs could then be metabolized to arachidonate, which regulates cell activation after the production of eicosanoids (Fig. 1A) .
Although, the individual reactions shown in Fig. 1A can occur, there is no direct evidence at present to link the LPPs to cannabinoid signaling.
Ecto-LPP1 activity also promotes uptake of sphingosine derived from S1P by human lung endothelial cells (30) . This increases intracellular S1P formation through sphingosine kinase-1 (30). Internal S1P is then able to activate internal signaling cascades ( Table 1 ). The balance between the formation of ceramide versus S1P is a critical regulator of cell death versus survival (19, 31) . Therefore, dephosphorylation of internal S1P by an LPP or SPP could help to determine the fate of the cell.
Work with FTY720 also demonstrates a role for the LPPs. FTY720 is a sphingosine analogue that is used as an immunomodulatory drug for treating multiple sclerosis. FTY720 is converted to FTY720-P by sphingosine kinase-2 (32). Lysates from cells that overexpressed LPP1, -2 and -3 showed that only LPP3 dephosphorylated FTY720-P and between the SPPs, only SPP1 showed activity. In intact cells, LPP3 acted as an ecto-phosphatase to control the equilibrium between FTY720 and FTY720-P that was observed in vivo (32) . This result is surprising compared to the broad substrate preference of the LPPs for lipid phosphates (1, 2) . In other studies LPP1a had the highest activity and affinity for FTY720-P (33) suggesting that the first extracellular loop, which is different in LPP1a compared to LPP1, plays a role in substrate recognition.
LPP1 dephosphorylates exogenous C1P (22) to produce ceramides that can be converted to C1P once they enter the cell. This mechanism could explain how exogenous C1P increases intracellular C1P thus activating cytosolic PLA 2 and leading to arachidonate and prostaglandin E 2 production (34).
Despite this weight of evidence for the importance of ecto-LPP activities, it has been questioned whether the LPPs regulate cell signaling based on conceptual problems. Namely, Studies with transgenic mice that over-express LPP1 unexpectedly demonstrated no significant differences in circulating LPA concentrations compared to control mice (9).
However, this work did not evaluate LPA turnover, which could be a self-regulating process since both LPA and S1P are product inhibitors of ATX (35). This observation shows that the regulation of LPA and S1P metabolism can interact at the levels of both ATX and the LPPs. Recent work also shows that exogenously added S1P is cleared from blood within [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] min and this process depends on a cell-associated phosphatase activity (36) .
Non-catalytic actions of the LPPs on the cell surface
Human LPP3 contains an exposed RGD cell adhesion sequence. hLPP3 expression increases cell/cell interactions through α v β 3 and anti-α 5 β 1 integrins, but mutation to RGE did not produce this effect (37) . Mouse and rat LPP3 contain RGE instead of RGD, but subsequent work showed that murine LPP3 also interacted with α 5 β 1 and α v α 3 integrins (38) . Also, anti-LPP3
antibody blocked bFGF-and VEGF-induced capillary morphogenesis of endothelial cells. This suggests a role for LPP3 in controlling angiogenesis through integrin interactions (39) as well as integrin-independent mechanisms.
Intracellular functions of the lipid phosphate phosphatases
Lipid phosphates and their dephosphorylated products regulate cell signaling (Table 1) and, therefore, the LPPs could regulate this balance (1 produces PA, which the LPPs convert to DAG (Fig. 1B) . Increasing LPP activity decreases PA concentrations (1) and/or increases those of DAG (1, 2, (40). PA activates a variety of intracellular signaling targets (Table 1) . It is proposed that LPP2, but not LPP3, could be functionally linked to phospholipase D1, which produces a PA-dependent recruitment of sphingosine kinase-1 to produce S1P in the perinuclear compartment (21) (Fig. 1B) . S1P
activates ERK, it stimulates cell division and protects against apoptosis. Although most actions of S1P are mediated through cell surface receptors, S1P can stimulate intracellular signaling cascades including the mobilization of intracellular Ca 2+ (19) .
DAG produced from PA can theoretically activate classical and novel protein kinase Cs and RasGRP (Table 1 ). However, it was proposed that the fatty acid compositions of DAGs derived from PC do not activate the protein kinase Cs compared to polyunsaturated DAGs produced from phosphatidylinositol 4,5-bisphosphate (41).
PA can also be metabolized to LPA (Fig. 1B) . Intracellular LPA can activate nuclear LPA 1 receptors that regulate pro-inflammatory gene expression. Polyunsaturated LPA stimulates PPARγ receptors (Table 1 ) (42), although this latter conclusion is disputed (43) . Additionally, LPA can be released by cells (4) and the level of LPP expression could regulate this process.
LPPs can also degrade C1P, which is involved in inflammation. C1P production activates Increasing LPP2 activity in fibroblasts increases entry into S-phase of the cell cycle, whereas decreasing the activity has the opposite effect (47) . LPP1 and LPP3 did not modify Sphase entry, demonstrating the specificity of the LPP2 effect. The premature entry into S-phase caused by increased LPP2 activity resulted in G2/M arrest after 15 to 35 passages. These cells eventually exited the cell cycle and they exhibited a senescent phenotype (47) . Some oncogenes induce premature senescence after initially stimulating cell proliferation and this may prevent malignancy (47) . Mice that over-express LPP1 have decreased birth weight, sparse curly hair, and defective spermatogenesis causing infertility (9) . Fibroblasts from these mice showed decreased LPA-induced migration (40, 46) and increased DAG concentrations after stimulation with phorbol ester (9) . There were no significant differences in ERK activation in response to stimulating the cells with LPA, S1P, EGF or PDGF (9) . However, in subsequent work, ERK activation in response to LPA, S1P and PDGF was decreased (40) . The combined results support the hypothesis that LPP1 regulates intracellular signaling. However, circulating LPA concentrations were not lower in the LPP1 over-expressing mice and the proposed role of the ecto-LPP1 activity was not demonstrated (9) . By contrast, studies described above with transgenic mice that have decreased LPP1 expression (Ppap2a tr/tr ) showed that LPP1 controls LPA removal from the blood, which increases circulating LPA levels. Otherwise, these mice display no obvious phenotype.
Lessons from animal models
LPP2 knockout mice are fertile and viable with no obvious phenotype (48) . This may appear to be incompatible with the proposal that LPP2 regulates cell cycle progression (47) .
LPP2 regulates the timing of S-phase entry, but it is not essential for cell-cycle progression.
Several genes that regulate progression into late G1 or entry into S-phase have been knocked out in mice without lethality or major phenotype, including genes that encode for CDK4, CDK6, CDK2, and cyclins D1, D2, D3, E1 or E2 (47) . Likewise, deletion of LPP2 should not result in lethality or a major phenotype.
Conclusions
The LPPs participate in cell signaling by modifying the balance between the effects of lipid phosphates versus their dephosphorylated products. They act as ecto-enzymes in isolated cells. Evidence is now appearing that the LPPs degrade extracellular LPA and S1P in vivo, but more work is required using suitable animal models. This ecto-activity regulates the turnover and availability of circulating LPA and S1P, thus controlling the activation of families of G-protein coupled receptors for these lipids. Secondly, the MAG and sphingosine that is produced is taken up by cells and rephosphorylated. The resulting intracellular LPA and S1P can then activate their own signaling cascades. In the case of LPP3, the presence of external integrin-binding domains modifies cell/cell interactions. 
